Smoking Clinical Trial
Official title:
Pharmacogenetics, Emotional Reactivity and Smoking Cessation: Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal
Objectives:
- To evaluate neural correlates associated with emotional processing during nicotine
withdrawal preferentially involving the amygdala and associated areas within the
corticolimbic and mesolimbic circuitry. We hypothesize that relative to a pre-quit
baseline, post-quit nicotine withdrawal will result in increased activity to negative
emotional cues, in contrast to other cues, in one or more areas of interest, and
particularly in the right cerebral hemisphere.
- To determine if bupropion and varenicline moderate patterns of brain activation during
post-quit nicotine withdrawal. We hypothesize that relative to placebo, bupropion and
varenicline will attenuate the effects of post-quit nicotine withdrawal on emotional
processing, reducing activation to negative emotional cues, relative to other cues, in
one or more areas of interest, and particularly in the right cerebral hemisphere.
- To determine if genotype (DRD2 TaqA2 allele and the ins variant of the -141C ins/del
DRD2) moderates patterns of brain activation during post-quit nicotine withdrawal.
Before you begin participation in this study, you will be asked to provide the names and
addresses of 3 contacts (family member/friends) who will know your current contact
information. This is so study researchers can stay in contact with you throughout the study.
This is in case study researchers may need to reach you in order to reschedule your
appointment time. You will also be asked to sign a letter giving your contacts permission to
provide your contact information to the study staff.
If the staff is not able to reach you, they may try to locate you through telephone
directory assistance or the internet. If the study staff is still unable to locate you, they
may use a locator service, such as Transunion or the National Change of Address (NCOA)
database, which is maintained by the United States Postal Service.
If you agree to take part in this study, you will be asked to come to the Behavioral Science
Research Clinic at M. D. Anderson for up to 2 laboratory sessions. One session will be while
you are smoking, and one session will be while you are abstinent from smoking (not smoking).
At each of these sessions, you will have functional magnetic resonance imaging (fMRI) of
your brain while you are looking at slides. fMRI involves a scanner that uses a large
magnet, instead of x-rays, to take pictures of the inside of your body. The slides will
include pictures of people, nature scenes, artwork, victims of car crashes, medical
procedures (such as open surgery or autopsy), and nude people. You will be shown examples of
these slides before having the fMRI, and you will be given the opportunity to withdraw from
this study at that time. If you choose to continue on this study, you will have an fMRI
taken of your brain. This will involve being passed into a narrow tube-shaped scanner that
is open at both ends. During the fMRI, your brain electrical activity will be monitored. The
total time for each lab session will last about 1.5 hours.
You should not drink more than 2 cups of coffee or other caffeine drinks at least 2 1/2
hours before each session. This is because caffeine may affect brain functioning. Before one
or both of your sessions, you may be asked to not smoke from bedtime on the day before the
session until after the session on the next day. Before one or both of your sessions, you
may be asked to smoke as you would regularly. Additionally, you may be asked to smoke during
one or both of your laboratory sessions.
At each lab session, you will be asked to blow air through a carbon monoxide (CO) measuring
device. CO is a gas that is found (in higher levels) in the bodies of cigarette smokers. You
will also be asked questions about your smoking habits; your health and medical condition;
and about any medications you are taking. You will also be asked to complete some
questionnaires that will ask about your mood and feelings. You may be asked to complete
these questionnaires before, during, or after the fMRI.
At the end of this study, you will be able to ask questions about the results of this study
and about procedures you have experienced during this study.
Your participation in this part of the study will last about 2 weeks. It will end after your
last lab session. You will still be considered a participant in the main study (Protocol
2003-1024) and may have additional visits, questionnaires, and other activities to complete.
This is an investigational study. Up to 72 participants will take part in this study. All
will be enrolled at M. D. Anderson.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02649556 -
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
|
N/A | |
Completed |
NCT03901066 -
Smoking Dependence and Periodontitis
|
||
Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT03305978 -
Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
|
N/A | |
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT06105424 -
BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability
|
N/A | |
Active, not recruiting |
NCT02752022 -
Monitoring the Transition From Smoking to E-cigarettes
|
||
Completed |
NCT02901171 -
The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation
|
N/A | |
Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
Completed |
NCT04340830 -
The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants
|
N/A | |
Completed |
NCT02912000 -
TEACH: Technology Evaluation to Address Child Health
|
N/A | |
Completed |
NCT02949648 -
Electronic Cigarette Use and Quitting in Youth
|
N/A | |
Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
Completed |
NCT02246114 -
Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women
|
N/A | |
Completed |
NCT02008292 -
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
|
N/A | |
Completed |
NCT01954407 -
Young Adults' Responses to Anti-smoking Messages
|
N/A | |
Completed |
NCT03448900 -
Intervention Study for Smoking Cessation in Spanish College Students
|
N/A |